Price (delayed)
$10.38
Market cap
$1B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.27
Enterprise value
$986.19M
Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime
There are no recent dividends present for AVDL.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.